SCHEMBL12065255

SCHEMBL12065255

CCOC(c1ccc(OC(F)(F)F)cc1)c1nc2cc(F)ccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
SCN10A Q9Y5Y9 1/20 0.40
TRPA1 O75762 2/20 0.37
PDE2A O00408 7/20 0.36
MLKL Q8NB16 1/20 0.36
TRPV4 Q9HBA0 1/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
TRPV1 Q8NER1 2/20 0.35
GPR139 Q6DWJ6 1/20 0.35
ALPL P05186 1/20 0.34
ALPI P09923 1/20 0.34
ALPG P10696 1/20 0.34
DPP4 P27487 1/20 0.34
NR3C2 P08235 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL14762710 0.94 PDE2A (0.38) SCN10APDE2AMLKLGPR139
Phosphoric Acid SCHEMBL14763404 0.94 PDE2A (0.38) SCN10APDE2AKMT2ATRPV1GPR139
SCHEMBL12066025 0.92 SCN10A (0.45) SCN10APDE2AMLKLMEN1HTT
SCHEMBL12065659 0.92 SCN10A (0.39) SCN10ATRPA1PDE2AMLKLTRPV4
Fumaric Acid SCHEMBL14836591 0.92 PDE2A (0.37) SCN10APDE2AMLKLKMT2AGPR139
Maleic Acid SCHEMBL14763282 0.92 PDE2A (0.37) SCN10APDE2AMLKLKMT2AGPR139
SCHEMBL12066550 0.89 MLKL (0.43) SCN10APDE2AMLKLMEN1HTT
SCHEMBL14762773 0.89 SCN10A (0.43) SCN10APDE2AMLKLMEN1HTT
SCHEMBL12065615 0.89 SCN10A (0.38) SCN10ATRPA1PDE2AMLKLTRPV4
SCHEMBL12066012 0.89 MEN1 (0.45) SCN10APDE2AMLKLMEN1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US claimed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US claimed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
US-9096531-B2 Fused imidazole derivative TOA EIYO LTD. (JP) 2015-08-04 US disclosed
EP-2578573-A1 FUSED IMIDAZOLE DERIVATIVE TOA Eiyo Ltd. (JP) 2013-04-10 EP disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE TOA EIYO LTD. (JP) 2013-03-14 US disclosed
WO-2011148956-A1 FUSED IMIDAZOLE DERIVATIVE トーアエイヨー株式会社 (JP) 2011-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065896-A1 FUSED IMIDAZOLE DERIVATIVE CACNA1E, CACNA1G, CACNA1A SCN10A 85/4885TRPA1 58/4885PDE2A 1306/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.